According to the latest news from Caixin.com, a person from the State Food and Drug Administration confirmed to Caixin reporter
Despite the peak of the Ebola epidemic, there are no specific drugs that have been clinically validated. A project announced by the University of Leeds on the 11th will use the software running on the supercomputer to "decode" the Ebola virus to find ways to inhibit viral replication and growth, thereby accelerating the development of therapeutic drugs.
Traditionally, new drug development requires biological testing of hundreds of pharmaceutical ingredients in the laboratory, a process that often takes a lot of time. According to the Leeds team, in order to improve efficiency, they will run a software on a supercomputer that records data on 1 million pharmaceutical ingredients and pairs them with key protein data from Ebola. Finally, find the ingredients that can affect the function of these proteins. The bioassay is then used to further verify the optimal ingredients selected by the computer.
According to the research team, they will focus on the two key proteins of the Ebola virus, "NP" and "VP30", which play a key role in the replication and growth of the virus, so if they can be found to affect them The active pharmaceutical ingredients are expected to develop more targeted anti-Ebola drugs.
Mark Harris, a professor of virology at the University of Leeds who led the project, said that after the Ebola outbreak, most of the research activities centered on how to use existing drugs to form treatment programs or develop Ebola vaccines. Explore the structure of Ebola virus proteins in order to find the most suitable pharmaceutical ingredients, and based on this, develop antiviral drugs for Ebola." (奇健生物 www.qjbio.com.cn)